Skip to main content

180 publications

Name Date Type Actions

2023 ANNUAL RESULTS

Annual sales: €529m (stable at constant exchange rates)
Essentials sales: €313m (+4.5% at constant exchange rates)
Net income - Group share: €56m (10.5% of sales)
EBITDA: €113m (21.3% of sales)
Free cash-flow: €89m

20/03/2024 Public releases

Annual sales 2023: €529 million

Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates)

24/01/2024 Public releases

Sales 3rd quarter 2023: 136M€

The Vetoquinol Group posted sales of €136 million in Q3 2023, up +1.3% on a reported basis and +5.1% at constant exchange rates. Over the same period, Vetoquinol recorded a negative currency impact of -€5 million, linked to the Americas and Asia Pacific/Rest of World territories.

26/10/2023 Public releases

2023 HALF-YEAR RESULTS

Sales: €256m (-5.4% as reported)
Essentials products sales: €151m (59% of Group sales)
Net income - Group share: €32m (12.6% of sales)
EBITDA*: €54m (20.9% of sales)
Cash-flow generation: €31m

07/09/2023 Public releases

Q1 2023 Sales: €145M

Vetoquinol recorded sales of €145 million for the first three months of the 2023 financial year, up 7.7% on a reported basis and 7.2% at constant exchange rates.

20/04/2023 Public releases

Availability of the 2022 universal registration document

On 13 April 2023, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).

13/04/2023 Public releases

2022 ANNUAL RESULTS

Annual sales: €540m (up 3.6% as reported)
Essentials sales: €304m (up 4.5% as reported)
EBIT before depreciation of acquired assets: €99m (18.3% of sales)
Net income - Group share: €48m (8.9% of sales)
EBITDA: €118m (21.9% of sales)
Free cash-flow: €63m

23/03/2023 Public releases

Annual sales 2022

Total group Sales: €540 million (up 3.6% as reported)
Annual Sales of Essential products: €304 million (up 4.5% as reported)

18/01/2023 Public releases

First nine months 2022 sales: €405M

In line with year-end outlook

12/10/2022 Public releases

2022 HALF YEAR RESULTS Additional information on the Group’s strategy

Following the conference call organised on 15 September 2022 to present its half-year results, Vetoquinol would like to provide some additional information on the strategy implemented and its outlook.

23/09/2022 Public releases , Half Year Report

2022 HALF YEAR RESULTS

Sales: €271m (up 6.0% as reported)
Essentials sales: €154m (up 9.8% as reported)
EBIT before depreciation of acquired assets: €52m (19.0% of sales)
Net income - Group share: €21m (7.9% of sales)
EBITDA: €62m (22.9% of sales)

15/09/2022 Public releases

H1 2022 Sales

H1 2022 Sales: €271m, up 6.1%
+2.0% on a like-for-like basis
H1 2022 Essentials Sales: €154m, up 9.8%
+6.8% on a like-for-like basis

20/07/2022 Public releases

Availability of the 2021 universal registration document

Vetoquinol informs that it has filed its 2021 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 22th, 2022.

22/04/2022 Public releases

Q1 2022 SALES: €135M

Q1 2022 SALES: €135M
(UP 5.5% AS REPORTED, UP 2.2% AT CONSTANT EXCHANGE RATES)
Q1 2022 ESSENTIALS SALES: €77M
(UP 8.1% AS REPORTED, UP 5.5 AT CONSTANT EXCHANGE RATES)

13/04/2022 Public releases

2021 Annual results

ALL FINANCIAL INDICATORS UP.
Annual sales: €521m (up 21.9% as reported).
Essentials sales: €296m (up 34.0% as reported).
EBIT before depreciation of acquired assets: €101m (up 54.5%).
Net income - Group share: €63m (up 226.9%).

24/03/2022 Public releases

Double-digit growth in 2021

Total Group Sales: €521 million (up 21.9% as reported)
Annual Sale of Essential products: €296 million (up 34.0% as reported)

20/01/2022 Public releases

Third quarter revenues: €132 million

14/10/2021 Public releases

2021 first half results

2021 Half year results

29/07/2021 Public releases

Availability of the 2020 universal registration document

Vetoquinol informs that it has filed its 2020 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 28th, 2021.

28/04/2021 Public releases

Q1 2021 sales

Q1 2021 sales : €128M (up 28% at constant exchange rates, up 24% as reported)
Q1 2021 essential sales : €72.6M (up 38% at constant exchange rates, up 36% as reported)

15/04/2021 Public releases

2020 annual results 2020 sales: €427.5m (up 8.0% as reported)

EBIT before depreciation of assets arising from acquisitions: €65.3m (up 33.5%)
Net income - Group share: €19.2m (4.5% of sales)
Cash flow: €92.2m

01/04/2021 Public releases

Vetoquinol acquires the rights for Profender® from Elanco Animal Health for Canada

February 8th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Canadian rights to Profender® product family from Elanco Animal Health.

08/02/2021 press release excluding results

Vetoquinol wins the Animal Pharm’s award for best European company 2020

February 8th, 2021 (Lure, France) - Vetoquinol announced today it has been awarded “Best European Company 2020” by Animal Pharm.

08/02/2021 Public releases

2020 sales: €427.5M (up 8.0% as reported, up 10.9% at constant exchange rate) essentials sales: €220.6M (up 15.7% as reported, up 17.3% at constant exchange rate)

Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams, whose hard work and exemplary dedication allowed us to manage the impact of the health crisis. Year on year, we achieved double-digit sales growth at constant exchange rates, driven by our Essentials products. This momentum accounts for additional sales of €43 million (at constant exchange rates). We also completed a major acquisition in the form of the Drontal® and Profender® product ranges, entailing three structural effects for Vetoquinol: a scale effect, a product mix effect in the Essentials range and potential extensions, the first of which has been confirmed in January 2021 for the Australian market. We are optimistic for our business outlook in 2021, while being vigilant in relation to the global sanitary situation.

21/01/2021 Public releases

Orion Animal Health and Vetoquinol expand collaboration - Vetoquinol to distribute Orion’s Clevor® in the USA and Orion to distribute Drontal® and Profender® products in Finland, Hungary and Romania

Orion Animal Health and Vetoquinol are expanding their collaboration with new distribution agreements.

18/01/2021 Public releases

Vetoquinol acquires the rights for Drontal® and Profender® families from Elanco animal health for Australia

January 11th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Australian rights to Drontal® and Profender® product families from Elanco Animal Health.

11/01/2021 Public releases

Q3 2020 sales: €114.5 million* (Up 14.3%)

Vetoquinol posted sales of €114.5 million for the third quarter of 2020, up 14.3% as reported compared to the same period last year.

15/10/2020 Public releases

VETOQUINOL, SNGTV and FARMVETSYSTEMS sign a partnership agreement to offer a common, innovative digital solution to the veterinary healthcare market. September 28th, 2020 (Paris, France) VETOQUINOL, FARMVET SYSTEMS and SNGTV have signed a partnership agreement aimed at offering a common solution highlighting the complementarity of their two software, VetIMPRESS and Vetélevage to farm vets. Aware of their shared philosophy aimed at optimizing vets actions thanks to new digital technologies, they are pooling these two software programs to strengthen the role of farm vets in animal health and welfare.

28/09/2020 Public releases

Vetimpress delivering digital solutions to farm vets with a growing network of partnerships

September 21st, 2020 (Northern Ireland) – VetIMPRESS the secure data management platform has recently implemented a series of integrations, reinforcing its position as a leading source of information for farm animal vets. The platform has grown its connections to over 100 external sources across 10 countries. The partnerships are set to improve connectivity across the industry, providing a single source of truth to better inform ethical, safe and productive veterinary decisions.
 

21/09/2020 Public releases

Vetoquinol finalizes the acquisition of Profender® and Drontal® product families

September 1st, 2020 (Lure, France) – Vetoquinol confirms the completion of the acquisition of Profender® and Drontal® product families for the European Economic Area and the UK. This acquisition is effective from August 1st, 2020.

02/09/2020 Public releases

2020 first half results consolidated sales: €196.1m (up 7.5% at constant exchange rates) net income group share: €15.1m (7.7% of sales)

At its meeting on July 29, 2020, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the first half 2020 financial statements. The auditors have completed their audit of the financial statements and will shortly issue their report thereon.

30/07/2020 Public releases

Vetoquinol is moving forward with the acquisition of Profender® and Drontal® and related pipeline assets following communication from the European commission

June 9th, 2020 (Lure, France) - The European Commission (EC) has approved, under the EU merger Regulation, the proposed acquisition of Bayer’s Animal Health Division by Elanco Animal Health.

09/06/2020 Public releases

Dominique Derveaux appointed Group Chief Operations Officer Effective April 1, 2020, Vetoquinol’s Board of Directors has appointed Dominique Derveaux Group Chief Operations Officer. In this capacity, he will run the Business, Marketing & Medical, Industrial, and Information Systems departments. He will report to Vetoquinol CEO Matthieu Frechin.

28/04/2020 Public releases

Availability of the 2019 universal registration document

Vetoquinol informs that it has filed its 2019 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 23, 2020.

23/04/2020 Public releases

Q1 2020 sales €103.4 million (Up 13.7%)

Vetoquinol Group sales for Q1 2020 amounted to €103.4 million, up 13.7% as reported and up 13.4% at constant exchange rates.

16/04/2020 Public releases

2019 annual results: group sales €396.0M, up 6.1% at constant exchange rates. Net income group share: €28.6M (7.2% of sales)

At its meeting on March 24, 2020, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2019 financial statements. The auditors have completed their audit of the financial statements and will shortly issue their report thereon.

26/03/2020 Public releases

Covid-19: Vetoquinol donates masks to neighboring healthcare facilities

Vetoquinol S.A, the animal health laboratory based in Lure (70) has decided to donate more than 6000 masks to hospitals and associations in the region. This is a civic action to help, amongst others, hospitals in the Belfort Montbéliard, Vesoul and Saint-Rémy regions.

20/03/2020 Public releases

Vetoquinol to acquire rights for Profender® and Drontal® from Elanco Animal Health for the European economic area and the UK

February 12 th , 2020 (Lure, France) - Vetoquinol has agreed terms to acquire the European Economic area and UK rights to Profender® and Drontal® product families from Elanco Animal Health.

12/02/2020 Public releases

2019 sales: €396.0 million (Up 7.6%)

The Vetoquinol Group posted 2019 sales of €396.0 million, up 7.6% as reported and up 6.1% at constant exchange rates.

23/01/2020 Public releases

Vetoquinol and Klox Technologies Announce Global Animal Health Collaboration Agreement

December 12, 2019 (Lure, France) - Vetoquinol S.A. and Klox Technologies Limited, a subsidiary of Klox Technologies Inc., have entered into an exclusive global licensing agreement, excluding the People’s Republic of China.

13/12/2019 Public releases

Q3 2019 sales: €100.2 million (Up 11.0%)

The Vetoquinol Group posted sales of €100.2 million for the third quarter of 2019, up 11.0% as reported and up 9.4% at constant exchange rates compared to the same period last year.

16/10/2019 Public releases

First half 2019 results

At its meeting on July 24, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited first half 2019 financial statements.

25/07/2019 Public releases

Vetoquinol announces a new milestone in its industrial strategy

Vetoquinol, a leading global animal health player, today announces a plan to reorganize its production facilities in Europe. This decision is in line with the Group’s strategy of streamlining operations in order to improve its response to customer needs, whether vets, breeders or pet owners.

12/07/2019 Public releases

Combined ordinary and extraordinary general meeting May 21, 2019

The Combined Ordinary and Extraordinary General Meeting of Vetoquinol shareholders was held on Tuesday May 21, 2019 in Lure, chaired by Etienne Frechin.

22/05/2019 Public releases

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2018 (french version)

The registration document of Vetoquinol relative to fiscal year 2018, including the annual financial report relative to fiscal year 2018, was filed with the Autorité des marchés financiers (“the AMF”) on April 29, 2019.

29/04/2019 Public releases

Q1 2019 sales: €90.9 million (up 3.7%)

Vetoquinol Group sales for Q1 2019 amounted to €90.9 million, up 2.3% at constant exchange rates and up 3.7% as reportedfrom the same period last year.

17/04/2019 Public releases

Vetoquinol finalizes acquisition of Clarion Biociencias in Brazil

Lure (France), April 16, 2019 - Vetoquinol today confirms the completion of its acquisition of Clarion Biociências, a Brazilian veterinary laboratory based in the state of Goiás.

 

16/04/2019 Public releases

Vetoquinol signs agreement to acquire Clarion Biociênciasin Brazil

On April 3rd, Vetoquinol signed an agreement to acquire Clarion Biociências, a Brazilian veterinary laboratory based in the state of Goiás.

04/04/2019 Public releases

Growth in all financial indicators in 2018. Essentials products sales: €179.4M (up 9.1% at constant exchange rates). Net income group share €36.3M (up 4.0%)

At its meeting on March 19, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited 2018 financial statements.

20/03/2019 Public releases

2018 sales: up 3.2% to €367.9 million

9.1% GROWTH IN ESSENTIALS PRODUCTS AT CONSTANT EXCHANGE RATES

 

24/01/2019 Public releases

Q3 2018 sales: €90.2 million Vetoquinol wins second prize for CSR in the Gaia Rating

In the first nine months of 2018, Vetoquinol recorded sales of €268.1 million, up 3.8% at constant exchange rates and 0.4% as reported.

18/10/2018 Public releases

Vetoquinol takes a major step towards digital innovation by acquiring an equity interest in Farmvet Systems Ltd

Vetoquinol, a leading global animal health company, has acquired a majority interest in Farmvet Systems Ltd. A thriving start-up based in Northern Ireland, Farmvet Systems digital know-how enables the strengthening of the role of the veterinary practitioner on cattle farms.

06/09/2018 Public releases

First half 2018 results

At its meeting on July 25, 2018, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited first half 2018 financial statements.

26/07/2018 Public releases

Vetoquinol publishes its half-yearly financial report relative to fiscal year 2018

Vetoquinol publishes its half-yearly financial report relative to fiscal year 2018

26/07/2018 Public releases

Combined ordinary and extraordinary general meeting May 29, 2018

The Combined Ordinary and Extraordinary General meeting was held on Tuesday May 29, 2018 in Lure, chaired by Etienne Frechin.

29/05/2018 Public releases

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2017 (french version)

The registration document of Vetoquinol relative to fiscal year 2017, including the annual financial report relative to fiscal year 2017, was filed with the Autorité des marchés financiers (“the AMF”) on April 23, 2018. 

23/04/2018 Public releases

Q1 2018 sales: €87.6M like-for-like growth up 5.6%, 0.4% as reported growth of essentials products: up 6.8% as reported

Vetoquinol posted Q1 2018 consolidated sales of €87.6 million, up 5.6% like for like and 0.4% as reported, compared to the same period last year. Negative currency impacts of 5.2% were mainly related to the US and Canadian dollars and the Indian rupee. 

12/04/2018 Public releases

Strong growth in all key financial indicators in 2017 ebit up 9.4% to €46.0 million net income - group share up 25.2% to €34.8 million

At its meeting on March 14, 2018, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited 2017 financial statements. 

15/03/2018 Public releases

2017 sales: €352.2 million 7.6% like-for-like growth in essentials products

The Vetoquinol Group posted sales of €352.2 million for the 2017 financial year, up 1.0% like-forlike. After a negative currency impact of 0.5%, mainly linked to the US and Canadian dollars, reported growth amounted to 0.5%.  

23/01/2018 Public releases

Vetoquinol acquires Equity Stake in Plant Advanced Technologies PAT

Lure and Nancy - November 13, 2017: Vetoquinol, a leading player in the animal health sector, and Plant Advanced Technologies PAT, a plant biotechnology company, announce Vetoquinol’s acquisition of an equity stake in Plant Advanced Technologies PAT. The transaction was carried out via a €500,000 reserved capital increase at a price of €25 per share resulting in the veterinary group holding an equity stake of just over 2% in PAT. 

13/11/2017 Public releases

Q3 2017 sales of €88.3 million, up 5.2% at constant exchange rates

For the third quarter of 2017, the Vetoquinol Group posted sales of €88.3 million, up 5.2% from Q3 2016 at constant exchange rates.

17/10/2017 Public releases

Reference products up 6.1% like-for-like in H1 net income group share up 6.5% to €14.4 million

At its meeting on July 26, 2017, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the financial statements for the first half of 2017.

27/07/2017 Public releases

Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2017 (french)

Communiqué de mise à disposition  du rapport financier semestriel relatif à l’exercice 2017 

27/07/2017 Public releases

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2016 (french version)

The registration document of Vetoquinol relative to fiscal year 2016, including the annual financial report relative to fiscal year 2016, was filed with the Autorité des marchés financiers ("the AMF") on April 26, 2017.

26/04/2017 Public releases

Q1 2017 sales stable at €86.1 million

Consolidated sales for Q1 2017 amounted to €86.1 million, up 0.4% as reported from the same period last year. Sales were boosted by a 1.8% positive currency impact mainly related to non-European currencies. Q1 sales fell 1.4% like-for-like. 

13/04/2017 Public releases

All key financial indicators up in 2016

At its meeting on March 22, 2017, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2016 financial statements. 

22/03/2017 Public releases

2016 sales: €350.3 million 4.3% like-for-like growth

The Vetoquinol Group posted sales of €350.3 million for 2016, representing like-for-like growth of 4.3%. After a negative currency impact of 2.0% mainly linked to the British pound, Canadian dollar and Indian rupee, reported growth amounted to 2.3%.

26/01/2017 Public releases

September 2016 year-to-date sales: €257.5 million a 4.8% organic growth

Vetoquinol posted sales of €257.5 million for the first nine months of 2016, up 2.3% compared to the same period last year. Organic growth for the period came to 4.8%, curbed by a 2.5% negative currency impact. 

18/10/2016 Public releases

Vetoquinol launches its employer brand

The veterinary pharmaceutical company Vetoquinol launches its employer brand. For 83 years, Vetoquinol has been building its future, drawing on relationships of trust with its partners, the development of every employee, and its long-held belief of continuous improvement. Following on from its corporate brand, the company is now positioning itself as a high-quality employer.

29/09/2016 Public releases

Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2016 (french)

Communiqué de mise à disposition  du rapport financier semestriel relatif à l’exercice 2016 

28/07/2016 Public releases

Dynamic first half 2016

2016 Half year Financial Report

28/07/2016 Public releases

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2015 (french version)

The Registration document of Vetoquinol relative to fiscal year 2015, including the Annual financial report relative to fiscal year 2014, was filed with the Autorité des marchés financiers (“the AMF”) on April 26, 2016.

27/04/2016 Public releases

Q1 sales: €85.8M

Vetoquinol posted Q1 2016 sales of €85.8 million, representing organic growth of 7.7%. Changes in exchange rates resulted in a negative currency impact of 2.1%; reported sales for the first three months of 2016 grew by 5.6%.

19/04/2016 Public releases

2015 results sales of reference products up 9.4% ebit up 10.3%

At its meeting on March 18, 2016, the Vetoquinol S.A. Board of Directors reviewed the Group’s results and approved the 2015 financial statements.

21/03/2016 Public releases

2015 sales up 8.7% to €342.6 million

The Vetoquinol Group posted 2015 sales of €342.6 million, up 8.7% on reported data and up 3.8% at constant exchange rates. The Group benefited from a positive currency impact of 4.9% mainly linked to the US dollar, Indian rupee and British pound.

08/02/2016 Public releases

Vetoquinol et nippon Zenyaku Kogyo Co. ltd. signent un accord de joint-venture au Japon

Vetoquinol and Nippon Zenyaku Kogyo Co., Ltd., also operating under the trade name “Zenoaq”, announced today the signature of a joint-venture agreement to develop, register and market a range of animal health products in Japan.

03/12/2015 Public releases

September 2015 year-to-date sales up 8.7% to €251.8 million

Vetoquinol sales for the first nine months of 2015 rose 8.7% to €251.8 million, boosted by a positive currency impact of €13.7 million. Organic growth for the same period came to 0.7%.

22/10/2015 Public releases

VETOQUINOL launches UPCARD©, an innovative drug for congestive heart failure in dogs

Vétoquinol continues the deployment of its reference products with the European launch of UPCARD©, an innovative drug designed to treat congestive heart failure in dogs.

14/09/2015 Public releases

First half 2015 sales €167.2m, up 11.9%

The July 29, 2015 Vétoquinol SA Board of Directors meeting reviewed Group revenues and approved the H1 2015 financial statements.

30/07/2015 Public releases

Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2015 (french)

Le rapport financier semestriel relatif à l’exercice 2015 peut être consulté ou téléchargé sur les sites
Internet de :
- Vétoquinol (www.vetoquinol.com)
- l’AMF (www.amf-france.org)

30/07/2015 Public releases

Vétoquinol is eligible for new PEA-PME funds

Vétoquinol confirms that it qualifies for the PEA-PME investment product in accordance with Decree
n°. 2014-283 on 4 March 2014 reflecting the application of Article 70 of 2014 finance law (n°. 2013-
1278 dated 29 December 2013) which set the conditions of companies’ eligibility for the PEA-PME

23/05/2015 Public releases

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2015 (french version)

The registration document of Vétoquinol relative to fiscal year 2014, including the annual financial report relative to fiscal year 2014, was filed with the Autorité des marchés financiers (“the AMF”) on April 17, 2015.

20/04/2015 Public releases

Q1 2015 sales show solid growth at €81.3 million (up +11.0%)

Vétoquinol posted first quarter 2015 sales of €81.3 million (after currency gains of €4.5 million), up +11.0%. At constant exchange rates, first quarter 2015 sales amounted to €76.7 million, a +4.8% increase from €73.2 million in Q1 2014.

14/04/2015 Public releases

Reference products up +13.2%. net income up +9.3%

Lure, March 23, 2015 – At its meeting on March 17, 2015, the Vétoquinol S.A. Board of Directors reviewed the Group results and approved the 2014 financial statements.

23/03/2015 Public releases

Vétoquinol and Orion Pharma Animal Health enter into distribution collaboration

Vétoquinol and Orion Pharma Animal Health - a part of Orion Corporation - announce their collaboration regarding the distribution of Dexdomitor®, Antisedan®, Domitor® and Domosedan®. Vétoquinol becomes distributor in selected European countries of these Orion Sedative products.

05/02/2015 Public releases

2014 sales up 5.2% to €315.3 million

The Vétoquinol Group posted 2014 sales of €315.3 million, up 5.2% from the previous year. At constant exchange rates, sales rose by 6.3%. The Vétoquinol Group achieved organic growth of 1.4% in 2014.

22/01/2015 Public releases

Information relative au code de gouvernance

Lors de la réunion du Conseil d’administration du 16 décembre 2014, les administrateurs ont adopté le code de gouvernance Middlenext. Depuis 2008, Vétoquinol se référait au code AFEP-MEDEF.

20/12/2014 Public releases

Information relative au Code de Gouvernance (french)

Lors de la réunion du Conseil d’administration du 16 décembre 2014, les
administrateurs ont adopté le code de gouvernance Middlenext. Depuis
2008, Vétoquinol se référait au code AFEP-MEDEF.

18/12/2014 Public releases

Q3 2014 sales up 11.0%

The Vétoquinol Group reported Q3 2014 sales of €82.2 million, up 11.0% compared to the same period last year (up 11.1% at constant exchange rates).

23/10/2014 Public releases

Solid growth in Q2 2014: 8.8% first half net income up 4.2%

At its July 30, 2014 meeting, the Vétoquinol S.A. Board of Directors reviewed the Group results and approved the financial statements for the first six months of 2014.

31/07/2014 Public releases

Vétoquinol and Bioniche Life Sciences Inc. close sale of Bioniche Animal Health business

Lure, France and Belleville, Ontario, Canada, April 16, 2014 - Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced the closing of the sale of Bioniche’s Animal Health business to Vétoquinol. The two companies announced the signing of a share purchase agreement in February that was subject to the approval of Bioniche shareholders. At a Special Meeting of Shareholders held yesterday, 97.4% of the Shares that were voted were in favour of the transaction.

16/04/2014 Public releases

Reference products up 2.2% in Q1 2014

Lure, April 16, 2013 – Vétoquinol posted Q1 2013 sales of €75.5 million, compared to €77.0 million for the first quarter of 2012. Like-for-like sales amounted to €76.0 million, compared to €77.0 million in Q1 2012.

15/04/2014 Public releases

Vétoquinol is eligible for new PEA-PME funds

Lure (France), April 2, 2014 – Vétoquinol confirms that it qualifies for the PEA-PME investment product in accordance with Decree n°. 2014-283 on 4 March 2014 reflecting the application of Article 70 of 2014 finance law (n°. 2013-1278 dated 29 December 2013) which set the conditions of companies’ eligibility for the PEA-PME

02/04/2014 Public releases

2013 growth driven by reference products

Lure (France), March 12, 2014 – At its March 11, 2014 meeting, the Vétoquinol SA board of directors reviewed the Group results and approved the 2013 financial statements.

12/03/2014 Public releases

Vétoquinol to acquire the animal health business of Bioniche Life Sciences Inc.

LURE, FRANCE and BELLEVILLE, ONTARIO, CANADA, February 27, 2014 - Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced their signing of a share purchase agreement under which Vétoquinol has agreed to purchase Bioniche’s Animal Health business for the cash purchase price of CAD$61 million.

27/02/2014 Public releases

7.8% organic growth in Q4 2013

The Vétoquinol Group posted Q4 2013 sales of €80.1 million, up +7.8% like for like from Q4 2012.

23/01/2014 Public releases

Jean-Yves RAVINET appointed Group Chief Operating Officer

Lure (France), January 7, 2014 – The Vétoquinol Group announces the appointment of Jean-Yves Ravinet as Group Chief Operating Officer.

07/01/2014 Public releases

Vétoquinol continues to launch reference products

Lure (France), December 16, 2013 – In line with its strategy of developing products targeting fast-growing markets, the Vétoquinol Group expands its Flexadin® range world-wide and launches Zylkène® in the United States.

16/12/2013 Public releases

2013 3rd quarter sales show organic growth

Vétoquinol generated sales of €74.0 million in the 3rd quarter of 2013, a drop of 0.1% based on reported data, and a 4.4% increase at constant exchange rates.

24/10/2013 Public releases

The reference products demonstrate solid growth

Lure (France), August 29, 2013 – At its meeting on August 27, 2013, the Vétoquinol S.A. Board of Directors reviewed the Group’s results, and approved the financial statements for the first six months of 2013.

29/08/2013 Public releases